Kyverna Therapeutics (KYTX) Operating Income (2023 - 2026)
Kyverna Therapeutics posted quarterly Operating Income of -$41.4 million for Q1 2026, up 12.74% year-on-year from -$36.7 million in Q1 2025, and down 5.31% on a QoQ basis from -$39.3 million in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Operating Income data on file, last reported at -$41.4 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 12.74% year-over-year to -$41.4 million; the trailing twelve-month figure through Mar 2026 stood at -$163.8 million (down 1.95% YoY), and the FY2025 full-year result was -$169.8 million, down 19.09% from the prior year.
- Operating Income for Q1 2026 stood at -$41.4 million, down from -$39.3 million in the prior quarter.
- Across five years, Operating Income topped out at -$11.4 million in Q1 2023 and bottomed at -$47.4 million in Q1 2025.
- The 4-year median for Operating Income is -$38.7 million (2025), against an average of -$32.0 million.
- The widest annual swing landed in 2024, when Operating Income plunged 156.51%; it then grew 12.74% in 2026.
- A 4-year view of Operating Income shows it stood at -$21.4 million in 2023, then slumped by 91.99% to -$41.0 million in 2024, then grew by 4.29% to -$39.3 million in 2025, then declined by 5.31% to -$41.4 million in 2026.
- The last three Operating Income figures came in at -$41.4 million (Q1 2026), -$39.3 million (Q4 2025), and -$38.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | -41.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.37 Mn |
| Dec 31, 2025 | -39.28 Mn |
| Sep 30, 2025 | -38.73 Mn |
| Jun 30, 2025 | -44.41 Mn |
| Mar 31, 2025 | -47.41 Mn |
| Dec 31, 2024 | -41.04 Mn |
| Sep 30, 2024 | -38.77 Mn |
| Jun 30, 2024 | -33.44 Mn |
| Mar 31, 2024 | -29.36 Mn |
| Dec 31, 2023 | -21.38 Mn |
| Sep 30, 2023 | -16.28 Mn |
| Jun 30, 2023 | -13.30 Mn |
| Mar 31, 2023 | -11.45 Mn |